| Name | PF429242 dihydrochloride |
| Description | PF429242 dihydrochloride is a reversible and competitive inhibitor of S1P, with an IC50 of 175 nM. |
| In vitro | 10 μM PF-429242 down-regulates the signal from an SRE-luciferase reporter gene in human embryonic kidney 293 cells and the expression of endogenous SREBP target genes in cultured HepG2 cells. In HepG2 cells, PF-429242 inhibits cholesterol synthesis, with an IC50 of 0.5 μM[1]. PF-429242 treatment also shows suppressive effects on DENV2 yields in the cultured fluids of human-derived HEK-293, Hep G2, and non-human-primate derived LLC-MK2 cells[2]. PF-429242 has potent antiviral against LCMV and LASV [3]. |
| In vivo | PF-429242 inhibits the expression of hepatic SREBP target genes, and the hepatic rates of cholesterol and fatty acid synthesis are reduced In mice[1]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 50 mg/mL (103.63 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (6.84 mM), Sonication is recommended. DMSO : 83.3 mg/mL (172.65 mM), Sonication is recommended.
|
| Keywords | Virus Protease | S1PReceptor | S1P Receptor | S1P | PF-429242 Dihydrochloride | PF429242 dihydrochloride | PF-429242 | PF429242 | PF 429242 Dihydrochloride | PF 429242 | Inhibitor | inhibit | Fatty Acid Synthase (FASN) |
| Inhibitors Related | Rifampicin | Phenytoin sodium | 2-Octanone | L-Lysine | L-Lysine hydrochloride | Ofloxacin | Vidarabine | Maltitol | Thymidine | trans-Chalcone | L-Carnitine | Danthron |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Protease Inhibitor Library | Anti-Viral Compound Library | Inhibitor Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |